COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS

The present disclose includes, among other things, compounds that treat or lessen the severity of a disorder, pharmaceutical compositions and methods of making and using the same.

BACKGROUND

Cancer is a term used for diseases in which abnormal cells divide without control and may invade other tissues. Cancer cells may also spread to other parts of the body through the blood and lymph systems.

There are more than 100 different types of cancer, with most cancers named for the organ or type of cell in which they start. For example, cancer that begins in the colon may be referred to as colon cancer; cancer that begins in basal cells of the skin may be referred to as basal cell carcinoma. Common types of cancer include breast cancer and lung cancer.

Cancer types can also be grouped into broader categories. The main categories of cancer include: carcinoma—cancer that begins in the skin or in tissues that line or cover internal organs; sarcoma—cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue; leukemia-cancer that starts in blood-forming tissue such as the bone marrow and causes large numbers of abnormal blood cells to be produced and enter the blood; lymphoma and myeloma—cancers that begin in the cells of the immune system; central nervous system cancers—cancers that begin in the tissues of the brain and spinal cord.

Several techniques for treating cancer are known in the art. Such techniques include chemotherapy, radiation therapy, surgery, and transplantation. Each of these techniques, however, have undesirable side effects and varying success rates. Therefore, a need exists to develop new methods for treating cancer and/or diseases associated with cellular proliferation.

SUMMARY

The present disclosure provides for compounds of Formula (I)

or a pharmaceutically acceptable salt or N-oxide thereof. Additionally, the present disclosure includes, among other things, pharmaceutical compositions, methods of using a compound of Formula (I).

The present disclosure provides for compounds of Formula (II)

or a pharmaceutically acceptable salt or N-oxide thereof. Additionally, the present disclosure includes, among other things, pharmaceutical compositions, methods of using a compound of Formula (II).

The present disclosure provides for compounds of Formula (III)

or a pharmaceutically acceptable or N-oxide salt thereof. Additionally, the present disclosure includes, among other things, pharmaceutical compositions, methods of using a compound of Formula (III).

DETAILED DESCRIPTION

The present disclosure includes, among other things, a compound of Formula (I)

or a pharmaceutically acceptable salt or N-oxide thereofwhereinA is —C(H)═ or —N═R1is selected from the group consisting of halogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6alkoxy, optionally substituted C1-C6haloalkoxy, —C(O)Ra, and —C(O)ORa;R2is selected from the group consisting of hydrogen, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, and —C(O)ORa,R2′is selected from the group consisting of optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, and —C(O)ORa;optionally, R2and R2′are taken together with the nitrogen on which they are attached to form optionally substituted 3-7-membered heterocyclyl or optionally substituted 5-9-membered heteroaryl;each R3is independently selected from the group consisting of halogen, —CN, —ORa, —N(Ra)2, —NO2, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, —C(O)ORa, and —C(O)N(Ra)2;each R4is independently selected from the group consisting of halogen, —CN, —ORa, —N(Ra)2, —NO2, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, —C(O)ORa, —C(O)N(Ra)2, optionally substituted phenyl, optionally substituted 3-7-membered heterocyclyl and optionally substituted 5-9-membered heteroaryl;each R5is independently selected from the group consisting of deuterium and halogen;each Rais independently is selected from the group consisting of hydrogen, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, optionally substituted 3-7-membered heterocyclyl, optionally substituted 5-9-membered heteroaryl, —C(O)Rb, and —C(O)ORb;optionally, two instances of Raare taken together with the nitrogen on which they are attached to form optionally substituted 3-7-membered heterocyclyl or optionally substituted 5-9-membered heteroaryl;each Rbis independently optionally substituted C1-C6aliphatic;n is 0, 1, 2, or 3;m is 0, 1, 2, 3, or 4; andp is 0, 1, 2, or 3.

Additionally, the present disclosure includes, among other things, a compound of Formula (I)

or a pharmaceutically acceptable salt thereofwhereinA is —C(H)═ or —N═R1is selected from the group consisting of optionally substituted C1-C6alkoxy, optionally substituted C1-C6haloalkoxy, —C(O)Ra, and —C(O)ORa;R2is selected from the group consisting of hydrogen, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, and —C(O)ORa;R2′is selected from the group consisting of optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, and —C(O)ORa;optionally, R2and R2′are taken together with the nitrogen on which they are attached to form optionally substituted 3-7-membered heterocyclyl or optionally substituted 5-9-membered heteroaryl;each R3is independently selected from the group consisting of halogen, —CN, —ORa, —N(Ra)2, —NO2, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, —C(O)ORa, and —C(O)N(Ra)2;each R4is independently selected from the group consisting of halogen, —CN, —ORa, —N(Ra)2, —NO2, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, —C(O)ORa, —C(O)N(Ra)2, optionally substituted phenyl, optionally substituted 3-7-membered heterocyclyl and optionally substituted 5-9-membered heteroaryleach Rais independently is selected from the group consisting of hydrogen, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Rb, and —C(O)ORb;optionally, two instances of Raare taken together with the nitrogen on which they are attached to form optionally substituted 3-7-membered heterocyclyl or optionally substituted 5-9-membered heteroaryl;each Rbis independently is selected from the group consisting of optionally substituted C1-C6aliphatic and optionally substituted C1-C6haloaliphatic;n is 0, 1, 2, or 3;m is 0, 1, 2, 3, or 4.

In some embodiments, present disclosure includes a compound of formula (I-a):

or a pharmaceutically acceptable salt or N-oxide thereof wherein R1, R4, and m are defined above and described in classes and subclasses herein.

In some embodiments, present disclosure includes a compound of formula (I-b)

or a pharmaceutically acceptable salt or N-oxide thereof, wherein R1, R4, Ra, and m are defined above and described in classes and subclasses herein.

In some embodiments, present disclosure includes a compound of Formula (II)

or a pharmaceutically acceptable salt or N-oxide thereof,whereinA is —C(H)═ or —N═R2is selected from the group consisting of —NH2, —NO2, —ORa, —O(CH2)1-3Ra, —C(O)ORa, —C(O)N(Ra)2, optionally substituted C1-C6aliphatic, and optionally substituted 5-9-membered heteroaryl;each R3is independently selected from the group consisting of halogen, —CN, —ORa, —N(Ra)2, —NO2, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, —C(O)ORa, and —C(O)N(Ra)2;each R4is independently selected from the group consisting of halogen, —CN, —ORa, —N(Ra)2, —NO2, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, —C(O)ORa, —C(O)N(Ra)2, optionally substituted phenyl, optionally substituted 3-7-membered heterocyclyl and optionally substituted 5-9-membered heteroaryl;each R5is independently selected from the group consisting of deuterium and halogen;each Rais independently is selected from the group consisting of hydrogen, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, optionally substituted 3-7-membered heterocyclyl, optionally substituted 5-9-membered heteroaryl, —C(O)Rb, and —C(O)ORb;optionally, two instances of Raare taken together with the nitrogen on which they are attached to form optionally substituted 3-7-membered heterocyclyl or optionally substituted 5-9-membered heteroaryl;each Rbis independently is selected from the group consisting of optionally substituted C1-C6aliphatic and optionally substituted C1-C6haloaliphatic;n is 0, 1, 2, or 3;m is 0, 1, 2, 3, or 4; andp is 0, 1, 2, or 3.

In some embodiments, present disclosure includes a compound of Formula (II):

or a pharmaceutically acceptable salt thereof,whereinA is —C(H)═ or —N═R2is selected from the group consisting of —C(O)ORa, —C(O)N(Ra)2, optionally substituted C1-C6aliphatic, and optionally substituted 5-9-membered heteroaryl;each R3is independently selected from the group consisting of halogen, —CN, —ORa, —N(Ra)2, —NO2, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, —C(O)ORa, and —C(O)N(Ra)2;each R4is independently selected from the group consisting of halogen, —CN, —ORa, —N(Ra)2—NO2, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, —C(O)ORa, —C(O)N(Ra)2, optionally substituted phenyl, optionally substituted 3-7-membered heterocyclyl and optionally substituted 5-9-membered heteroaryleach Rais independently is selected from the group consisting of hydrogen, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Rb, and —C(O)ORb;optionally, two instances of Raare taken together with the nitrogen on which they are attached to form optionally substituted 3-7-membered heterocyclyl or optionally substituted 5-9-membered heteroaryl;each Rbis independently is selected from the group consisting of optionally substituted C1-C6aliphatic and optionally substituted C1-C6haloaliphatic;n is 0, 1, 2, or 3;m is 0, 1, 2, 3, or 4.

In some embodiments, present disclosure includes a compound of formula (II-a):

or a pharmaceutically acceptable salt or N-oxide thereof wherein R2, R4, and m are defined above and described in classes and subclasses herein.

In some embodiments, the present disclosure includes a compound of Formula (II)

or a pharmaceutically acceptable salt or N-oxide thereof,whereinA is —C(H)═ or —N═;one of Q1and Q2is —N(Ra)— or —S— and the other is —C(H)═;R2is selected from the group consisting of —C(O)ORa, —C(O)N(Ra)2, optionally substituted C1-C6haloaliphatic, and optionally substituted 5-9-membered heteroaryl;each R3is independently selected from the group consisting of halogen, —CN, —ORa, —N(Ra)2, —NO2, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, —C(O)ORa, and —C(O)N(Ra)2;each Rais independently is selected from the group consisting of hydrogen, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Rb, and —C(O)ORb;optionally, two instances of Raare taken together with the nitrogen on which they are attached to form optionally substituted 3-7-membered heterocyclyl or optionally substituted 5-9-membered heteroaryl;each Rbis independently is selected from the group consisting of optionally substituted C1-C6aliphatic and optionally substituted C1-C6haloaliphatic;n is 0, 1, 2, or 3;m is 0, 1, 2, 3, or 4.

In some embodiments, present disclosure includes a compound of formula (III-a1) or (III-a2)

or a pharmaceutically acceptable salt or N-oxide thereof, wherein Raand R2are defined above and described in classes and subclasses herein.

In some embodiments, present disclosure includes a compound of formula (III-b1) or (III-b2)

or a pharmaceutically acceptable salt thereof, wherein A, Ra, and R2are defined above and described in classes and subclasses herein.

In some embodiments, R1is selected from the group consisting of halogen optionally substituted C1-C6alkyl, optionally substituted C1-C6alkoxy, optionally substituted C1-C6haloalkoxy, —C(O)Ra, and —C(O)ORa. In some embodiments, R1is selected from the group consisting of optionally substituted C1-C6alkoxy, optionally substituted C1-C6haloalkoxy, —C(O)Ra, and —C(O)ORa. In some embodiments, R1is optionally substituted C1-C6alkoxy. In some embodiments, R1is —OMe. In some embodiments, R1is —C(O)ORa. In some embodiments, R1is —C(O)OMe.

In some embodiments, R2is selected from the group consisting of hydrogen, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, and —C(O)ORa. In some embodiments, R2is selected from the group consisting of —C(O)ORa, —C(O)N(Ra)2, optionally substituted C1-C6aliphatic, and optionally substituted 5-9-membered heteroaryl. In some embodiments, R2is selected from the group consisting of —C(O)ORa, —C(O)N(Ra)2, optionally substituted C1-C6haloaliphatic, and optionally substituted 5-9-membered heteroaryl;

In some embodiments, R2′is selected from the group consisting of optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, and —C(O)ORa.

In some embodiments, R2and R2′are taken together with the nitrogen on which they are attached to form optionally substituted 3-7-membered heterocyclyl or optionally substituted 5-9-membered heteroaryl.

In some embodiments, R2and R2′are taken together with the nitrogen on which they are attached to form o optionally substituted 5-9-membered heteroaryl.

In some embodiments, R2is optionally substituted 5-membered heteroaryl. In some embodiments, R2is optionally substituted 5-membered heteroaryl comprising 1-3 heteroatoms selected from the group consisting of O, N, and S. In some embodiments, R2is optionally substituted 5-membered heteroaryl comprising 1-3 nitrogen atoms. In some embodiments, R2is optionally substituted oxazolyl or optionally substituted pyrazolyl.

In some embodiments, each each R3is independently selected from the group consisting of halogen, —CN, —ORa, —N(Ra)2, —NO2, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Ra, —C(O)ORa, and —C(O)N(Ra)2.

In some embodiments, each Rais independently is selected from the group consisting of hydrogen, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, optionally substituted 3-7-membered heterocyclyl, optionally substituted 5-9-membered heteroaryl, —C(O)Rb, and —C(O)ORb; optionally, two instances of Raare taken together with the nitrogen on which they are attached to form optionally substituted 3-7-membered heterocyclyl or optionally substituted 5-9-membered heteroaryl. In some embodiments, each Rais independently is selected from the group consisting of hydrogen, optionally substituted C1-C6aliphatic, optionally substituted C1-C6haloaliphatic, —C(O)Rb, and —C(O)ORb; optionally, two instances of Raam taken together with the nitrogen on which they are attached to form optionally substituted 3-7-membered heterocyclyl or optionally substituted 5-9-membered heteroaryl. In some embodiments, Rais optionally substituted C1-C6aliphatic. In some embodiments, Rais optionally substituted C1-C3alkyl. In some embodiments, Rais optionally substituted methyl.

In some embodiments, each Rbis independently optionally substituted C1-C6aliphatic. In some embodiments, each Rbis independently optionally substituted C1-C3alkyl. In some embodiments, Rbis independently optionally substituted methyl.

m, and n

In some embodiments, n is 0, 1, 2, or 3. In some embodiments, n is 1, 2, or 3. In some embodiments, m is 0, 1, 2, 3, or 4. In some embodiments, m is 1, 2, 3, or 4.

Compounds

In some embodiments, compounds of the present disclosure includes those from Table 1.

TABLE 1NO.Structure1234567891011121314151718192021222627293031323435363738394041424344454647484950515253545556575859606162636465666768697071727374757677787980818283848586878889909192939495969798
or a pharmaceutically acceptable salt thereof.

Definitions

The term “alkyl” refers to a straight or branched alkyl group. Exemplary alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

As used herein, the terms “heterocycle”, “heterocyclyl”, “heterocyclic radical”, and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term “nitrogen” includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or+NR (as in TV-substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms “heterocycle”, “heterocyclyl”, “heterocyclyl ring”, “heterocyclic group”, “heterocyclic moiety”, and “heterocyclic radical”, are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocyclyl ring. A heterocyclyl group may be mono- or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.

As used herein, “N-oxide” refers to the oxide of the nitrogen atom of a nitrogen-containing heteroaryl or heterocycle. N-oxide can be formed in the presence of an oxidizing agent such as m-chloroperbenzoic acid or hydrogen peroxide. N-oxide refers to an amine oxide, also known as amine-N-oxide, and is a chemical compound that contains N—O bond.

Combinations of substituents and variables envisioned by this disclosure are only those that result in the formation of stable compounds. The term “stable”, as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).

The compounds of the disclosure may contain one or more chiral centers and, therefore, exist as stereoisomers. The term “stereoisomers” when used herein consist of all enantiomers or diastereomers. These compounds may be designated by the symbols “(+),” “(−),” “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. The present disclosure encompasses various stereoisomers of these compounds and mixtures thereof mixtures of enantiomers or diasteromers may be designated “(f)” in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly.

The compounds of the disclosure may contain one or more double bonds and, therefore, exist as geometric isomers resulting from the arrangement of substituents around a carbon-carbon double bond. The symboldenotes a bond that may be a single, double or triple bond as described herein. Substituents around a carbon-carbon double bond are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with TUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the “E” and “Z” isomers. Substituents around a carbon-carbon double bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond.

Compounds of the disclosure may contain a carbocyclic or heterocyclic ring and therefore, exist as geometric isomers resulting from the arrangement of substituents around the ring. Substituents around a carbocyclic or heterocyclic ring may also be referred to as “cis” or “trans”, where the term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated “cis/trans.”

Individual enantiomers and diasteriomers of compounds of the present disclosure can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, (3) direct separation of the mixture of optical enantiomers on chiral liquid chromatographic columns or (4) kinetic resolution using stereoselective chemical or enzymatic reagents. Racemic mixtures can also be resolved into their component enantiomers by well known methods, such as chiral-phase liquid chromatography or crystallizing the compound in a chiral solvent. Stereoselective syntheses, a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the creation of a new stereocenter or during the transformation of a pre-existing one, are well known in the art. Stereoselective syntheses encompass both enantio- and diastereoselective transformations, and may involve the use of chiral auxiliaries. For examples, see Carreira and Kvaerno,Classics in Stereoselective Synthesis, Wiley-VCH: Weinheim, 2009.

Additionally, the present disclosure contemplates tautomers of the compounds as drawn herein.

The term “biological sample”, as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof. Examples of such purposes include, but are not limited to, blood transfusion, organ transplantation, biological specimen storage, and biological assays.

As used herein, a “therapeutically effective amount” means an amount of a substance (e.g., a therapeutic agent, composition, and/or formulation) that elicits a desired biological response. In some embodiments, a therapeutically effective amount of a substance is an amount that is sufficient, when administered as part of a dosing regimen to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, diagnose, prevent, and/or delay the onset of the disease, disorder, and/or condition. As will be appreciated by those of ordinary skill in this art, the effective amount of a substance may vary depending on such factors as the desired biological endpoint, the substance to be delivered, the target cell or tissue, etc. For example, the effective amount of a provided compound in a formulation to treat a disease, disorder, and/or condition is the amount that alleviates, ameliorates, relieves, inhibits, prevents, delays onset of, reduces severity of and/or reduces incidence of one or more symptoms or features of the disease, disorder, and/or condition. I

As used herein, the terms “treatment,” “treat,” and “treating” refer to partially or completely alleviating, inhibiting, delaying onset of, ameliorating and/or relieving a disorder or condition, or one or more symptoms of the disorder or condition, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In some embodiments, the term “treating” includes halting the progression of a disease or disorder. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence. Thus, in some embodiments, the term “treating” includes preventing relapse or recurrence of a disease or disorder.

A “pharmaceutically acceptable derivative” means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this disclosure that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this disclosure or an inhibitorily active metabolite or residue thereof.

The expression “dosage unit form” as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that total daily usage of compounds and compositions of the present disclosure will be decided by the attending physician within the scope of sound medical judgment. Specific effective dose level for any particular patient or organism will depend upon a variety of factors including disorder being treated and severity of the disorder, activity of specific compound employed; specific composition employed; age, body weight, general health, sex and diet of the patient; time of administration, route of administration, and rate of excretion of a specific compound employed; duration of treatment; drugs used in combination or coincidental with a specific compound employed, and like factors well known in the medical arts.

Alternative Embodiments

In an alternative embodiment, compounds described herein may also comprise one or more isotopic substitutions. For example, hydrogen may be2H (D or deuterium) or3H (T or tritium); carbon may be, for example,13C or4C; oxygen may be, for example,18O; nitrogen may be, for example,15N, and the like. In other embodiments, a particular isotope (e.g.,3H,13C,14C,18O, or15N) can represent at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 99.9% of the total isotopic abundance of an element that occupies a specific site of the compound.

Pharmaceutical Compositions

In some embodiments, the present disclosure provides a composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the amount of compound in compositions contemplated herein is such that is effective to measurably treat a disease or disorder in a biological sample or in a patient. In certain embodiments, the amount of compound in compositions of this disclosure is such that is effective to measurably treat a disease or disorder in a biological sample or in a patient. In certain embodiments, a composition contemplated by this disclosure is formulated for administration to a patient in need of such composition. In some embodiments, a composition contemplated by this disclosure is formulated for oral administration to a patient.

In some embodiments, compositions of the present disclosure may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. In some preferred embodiments, compositions are administered orally, intraperitoneally or intravenously. In some embodiments, sterile injectable forms of the compositions comprising one or more compounds of Formula (I) may be aqueous or oleaginous suspension. In some embodiments, suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. In some embodiments, sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. In some embodiments, among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In some embodiments, additional examples include, but are not limited to, sterile, fixed oils are conventionally employed as a solvent or suspending medium.

Pharmaceutically acceptable compositions comprising one or more compounds of Formula (I) may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In some embodiments, carriers used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. In some embodiments, useful diluents include lactose and dried cornstarch. In some embodiments, when aqueous suspensions are required for oral use, an active ingredient is combined with emulsifying and suspending agents. In some embodiments, certain sweetening, flavoring or coloring agents may also be added.

Pharmaceutically acceptable compositions comprising a compound of Formula (I) may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs. In some embodiments, pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of compounds of this disclosure include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

In some embodiments, an amount of a compound of the present disclosure that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, provided compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.

Methods of Using Compounds of the Present Disclosure

In some embodiments, the present disclosure provides a method for treating or lessening the severity of a disease or condition associated with cell proliferation in a patient comprising the step of administering to said patient a composition according to the present disclosure.

The term “disease or condition associated with cell proliferation”, as used herein means any disease or other deleterious condition in which cell proliferation is known to play a role. Accordingly, another embodiment of the present disclosure relates to treating or lessening the severity of one or more diseases in which cell proliferation is known to play a role. In some embodiments, a disease or condition associated with cell proliferation is cancer.

In some embodiments, administration of a compound of the present disclosure results in arrest of mitosis or change in DNA content.

In some embodiments, administration of a compound of the present disclosure results in arrest of mitosis. In some embodiments, mitotic arrest is defined as a 10-100% reduction in mitosis. In some embodiments, mitotic arrest is defined as a 20-100% reduction in mitosis. In some embodiments, mitotic arrest is defined as a 30-100% reduction in mitosis. In some embodiments, mitotic arrest is defined as a 40-100% reduction in mitosis. In some embodiments, mitotic arrest is defined as a 50-100% reduction in mitosis. In some embodiments, mitotic arrest is defined as a 60-100% reduction in mitosis. In some embodiments, mitotic arrest is defined as a 70-100% reduction in mitosis. In some embodiments, mitotic arrest is defined as a 80-100% reduction in mitosis. In some embodiments, mitotic arrest is defined as a 90-100% reduction in mitosis. In some embodiments, mitotic arrest is defined as a 100% reduction in mitosis.

In some embodiments, administration of a compound of the present disclosure results in change in DNA content. In some embodiments, change of DNA content is induction of polyploidy.

In some embodiments, compounds and compositions, according to a method of the present disclosure, may be administered using any amount and any route of administration effective for treating or lessening the severity of cancer. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, severity of the infection, particular agent, its mode of administration, and the like. Compounds of the present disclosure are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.

In some embodiments, cancer is selected from the group consisting of lung cancer and breast cancer. In some embodiments, cancer is lung cancer. In some embodiments, lung cancer is non-small cell lung cancer. In some embodiments, non-small cell lung cancer is lung adenocarcinoma. In some embodiments, cancer is breast cancer. In some embodiments, breast cancer is mammary cancer. In some embodiments, breast cancer is breast adenocarcinoma.

In some embodiments, pharmaceutically acceptable compositions of comprising compounds of the present disclosure can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, as an oral or nasal spray, or the like, depending on the severity of infection being treated. In certain embodiments, compounds of the present disclose may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain desired therapeutic effect.

In some embodiments, one or more additional therapeutic agents, may also be administered in combination with compounds of the present disclosure. In some embodiments, a compound of the present disclosure and one or more additional therapeutic agents may be administered as part of a multiple dosage regime. In some embodiments, a compound of the present disclosure and one or more additional therapeutic agents may be administered may be administered simultaneously, sequentially or within a period of time. In some embodiments, a compound of the present disclosure and one or more additional therapeutic agents may be administered within five hours of one another. In some embodiments, a compound of the present disclosure and one or more additional therapeutic agents may be administered within 24 hours of one another. In some embodiments, a compound of the present disclosure and one or more additional therapeutic agents may be administered within one week of one another.

In some embodiments, a compound of the present disclosure and one or more additional therapeutic agents may be formulated into a single dosage form.

General Methods

Unless stated otherwise, all the chemicals required for synthesis were purchased from commercially available suppliers and used without further purification.1H NMR spectra was determined with a Bruker Avance III-400 at 400 MHz. LC-MS analysis was performed on a platform equipped with Agilent LC-MS 1260-6110 or Agilent LC-MS 1260-6120, using a Waters X Bridge C18: 50 mm×4.6 mm×3.5 um column. Flash column chromatography was conducted with silica gel (200-300 mesh, Qingdao Haiyang Chemical Co. Ltd., China). Analytical and preparative TLC analysis were performed on GF254 silica gel plates (Yantai Jiangyou Inc., China). Unless otherwise noted, reagents and all solvents are analytically pure grade and were obtained commercially from vendors such as Chron Chemical or Energy-Chemical.

4-4-chloroquinoline-6-carboxamide (103.3 mg, 0.5 mmol, 1.0 eq), 3-methyl-5-(1H-pyrazol-1-yl)phenol (130.5 mg, 0.75 mmol, 1.5 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (156 mg, yield=90.6%, purity=93.2%)

4-chloroquinoline-6-carboxamide (103.3 mg, 0.5 mmol, 1.0 eq), 3-chloro-5-(1H-pyrazol-1-yl)phenol (117 mg, 0.6 mmol, 1.2 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (160 mg, yield=87.7%, purity=97.8%)

4-chloroquinoline-6-carboxamide (103.3 mg, 0.5 mmol, 1.0 eq), (R)-3-methoxy-5-((tetrahydrofuran-3-yl)oxy)phenol (210 mg, 1.0 mmol, 2.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (138 mg, yield=72.6%, purity=97.6%)

4-chloro-7-methoxyquinoline-6-carboxamide (142 mg, 0.6 mmol, 1.0 eq), 3,5-di(1H-pyrazol-1-yl)phenol (203 mg, 0.9 mmol, 1.5 eq) and K2CO3(331 mg, 2.4 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (77 mg, yield=85.5%, purity=91.7%)

4-chloro-7-methoxyquinoline-6-carboxamide (119 mg, 0.5 mmol, 1.0 eq), 3-chloro-5-(1H-pyrazol-1-yl)phenol (117 mg, 0.6 mmol, 1.2 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (175 mg, yield=88.6%, purity=97.2%)

4-chloro-7-methoxyquinoline-6-carboxamide (119 mg, 0.5 mmol, 1.0 eq), 3-methoxy-5-((tetrahydrofuran-3-yl)oxy)phenol (210 mg, 1.0 mmol, 2.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (205 mg, yield=99%, purity=93.9%)

4-bromoquinoline (104 mg, 0.5 mmol, 1.0 eq), methyl 3-hydroxy-5-methoxybenzoate (109 mg, 0.6 mmol, 1.2 eq) and K2CO3(138 mg, 1 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (112 mg, yield=72.5%, purity=98.6%)

Methyl 3-methoxy-5-(quinolin-4-yloxy) benzoate (50 mg, 0.162 mmol, 1.0 eq) and LiOH (20.4 mg, 0.485 mmol, 3.0 eq) were added to a round-bottom flask with a magnetic bat. Then 0.6 ml EtOH and 0.3 ml H2O were added as solvent. The reaction mixture was stirred overnight. When methyl 3-methoxy-5-(quinolin-4-yloxy)benzoate was consumed, the pH of reaction mixture was adjusted to 7 and some white solid formed, which was filtered and dried to give the product without further purification. (42 mg, yield=87.8%, purity=99%)

4-bromoquinoline (104 mg, 0.5 mmol, 1.0 eq), 3-hydroxy-5-methoxy-N-methylbenzamide (90.5 mg, 0.5 mmol, 1.0 eq) and K2CO3(138 mg, 1 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (127.9 mg, yield=83%, purity=99%)

4-bromoquinoline (104 mg, 0.5 mmol, 1.0 eq), 3-methoxy-5-(trifluoromethyl)phenol (96 mg, 0.5 mmol, 1.0 eq) and K2CO3(138 mg, 1 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (92 mg, yield=57.7%, purity=99%)

4-bromoquinoline (104 mg, 0.5 mmol, 1.0 eq), 3-methoxy-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenol (103 mg, 0.5 mmol, 1.0 eq) and K2CO3(138 mg, 1 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (158 mg, yield=94.8%, purity=93.5%)

4-bromoquinoline (124.8 mg, 0.6 mmol, 1.0 eq), N-(3-hydroxy-5-methoxyphenyl)acetamide (90.5 mg, 0.5 mmol, 1.0 eq) and Cs2CO3(326 mg, 1 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (141 mg, yield=91.6%, purity=99.52%)

4-bromoquinoline (125 mg, 0.6 mmol, 1.0 eq), dimethyl 5-hydroxyisophthalate (126 mg, 0.6 mmol, 1.0 eq) and K2CO3(331 mg, 2.4 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (49 mg, yield=24.23%, purity=99%)

4-chloro-6-methoxyquinoline (97 mg, 0.5 mmol, 1.0 eq), N-(3-hydroxy-5-methoxyphenyl)acetamide (91 mg, 0.5 mmol, 1.0 eq) and K2CO3(138 mg, 1.0 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (120 mg, yield=70.9%, purity=98.6%)

4-chloro-6-fluoroquinoline (72.63 mg, 0.4 mmol, 1.0 eq), N-(3-hydroxy-5-methoxyphenyl)acetamide (72.48 mg, 0.4 mmol, 1.0 eq) and K2CO3(110.56 mg, 0.8 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 2 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (65 mg, yield=49.8%, purity=99%)

6-bromo-4-chloroquinoline (72.75 mg, 0.3 mmol, 1.0 eq), N-(3-hydroxy-5-methoxyphenyl)acetamide (54.357 mg, 0.3 mmol, 1.0 eq) and K2CO3(110.56 mg, 0.8 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 2 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (68 mg, yield=58.5%, purity=99%)

4-chloro-6,7-dimethoxyquinoline (89.44 mg, 0.4 mmol, 1.0 eq), N-(3-hydroxy-5-methoxyphenyl)acetamide (72.476 mg, 0.4 mmol, 1.0 eq) and K2CO3(110.56 mg, 0.8 mmol, 2.0 eq) were added to a round-bottom flask with a magnetic bar, then 2 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (33.4 mg, yield=22.7%, purity=96.7%)

4-chloro-6,7-dimethoxyquinoline (134.8 mg, 0.6 mmol, 1.0 eq), methyl 3-hydroxy-5-methoxybenzoate (109.2 mg, 0.6 mmol, 1.0 eq) and K2CO3(165.6 mg, 0.6 mmol, 1.2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (130 mg, yield=58.56%, purity=98.2%)

4-chloro-7-methoxyquinoline-6-carboxamide (70.995 mg, 0.3 mmol, 1.0 eq), 3-methoxy-5-(1H-pyrazol-1-yl)phenol (57.06 mg, 0.3 mmol, 1.0 eq) and K2CO3(82.92 mg, 0.6 mmol, 2.0 eq) were added to a round-bottom flask with a magnetic bar, then 2 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (104 mg, yield=88.8%, purity=94.2%)

4-chloro-7-methoxyquinoline-6-carboxamide (94.66 mg, 0.4 mmol, 1.0 eq), N-(3-hydroxy-5-methoxyphenyl)acetamide (72.476 mg, 0.4 mmol, 1.0 eq) and K2CO3(261 mg, 0.8 mmol, 2.0 eq) were added to a round-bottom flask with a magnetic bar, then 2 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (57 mg, yield=37.4%, purity=89.3%)

methyl 4-chloro-7-methoxyquinoline-6-carboxylate (75.501 mg, 0.3 mmol, 1.0 eq), 3-methoxy-5-(1H-pyrazol-1-yl)phenol (57.06 mg, 0.3 mmol, 1.0 eq) and K2CO3(82.92 mg, 0.6 mmol, 2.0 eq) were added to a round-bottom flask with a magnetic bar, then 2 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (50.5 mg, yield=41.5%, purity=98.4%)

4-chloro-5H-pyrrolo[3,2-d]pyrimidine (91.8 mg, 0.6 mmol, 1.0 eq), methyl 3-hydroxy-5-methoxybenzoate (109.2 mg, 0.6 mmol, 1.2 eq) and K2CO3(165.6 mg, 1.2 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (60 mg, yield=33.5%, purity=82%)

4-chloro-5H-pyrrolo[3,2-d]pyrimidine (153 mg, 1.0 mmol, 1.0 eq), dimethyl 5-hydroxyisophthalate (210 mg, 1.0 mmol, 1.2 eq) and K2CO3(276 mg, 2.0 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 6 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (31 mg, yield=9.5%, purity=96%)

4-chlorothieno[3,2-d]pyrimidine (102.36 mg, 0.6 mmol, 1.0 eq), methyl 3-hydroxy-5-methoxybenzoate (109.2 mg, 0.6 mmol, 1.0 eq) and K2CO3(165.6 mg, 1.2 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (167 mg, yield=88%, purity=97.5%)

4-chlorothieno[3,2-d]pyrimidine (170 mg, 1.0 mmol, 1.0 eq), dimethyl 5-hydroxyisophthalate (210 mg, 1.0 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (280 mg, yield=81.4%, purity=96%)

4-chlorothieno[2,3-d]pyrimidine (85.3 mg, 0.5 mmol, 1.0 eq), methyl 3-hydroxy-5-methoxybenzoate (91.1 mg, 0.5 mmol, 1.0 eq) and K2CO3(138 mg, 1.0 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (83 mg, yield=52.5%, purity=98.7%)

methyl 4-chloroquinoline-6-carboxylate (132.98 mg, 0.6 mmol, 1.2 eq), N-(3-hydroxy-5-methoxyphenyl)acetamide (90.60 mg, 0.5 mmol, 1.0 eq) and Cs2CO3(325.82 mg, 1.0 mmol, 2.0 eq) were added to a round-bottom flask with a magnetic bar, then 2 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a solid. (44.8 mg, yield=24.5%, purity=97.40%)

7-chlorothieno[3,2-b]pyridine (101.778 mg, 0.6 mmol, 1.2 eq), N-(3-hydroxy-5-methoxyphenyl)acetamide (90.60 mg, 0.5 mmol, 1.0 eq) and Cs2CO3(325.82 mg, 1.0 mmol, 2.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (127.9 mg, yield=81.4%, purity=99%)

) 4-chloro-7-methoxy-N-methylquinoline-6-carboxamide (125.34 mg, 0.5 mmol, 1.0 eq), 3-methoxy-5-(1H-pyrazol-1-yl)phenol (114.12 mg, 0.6 mmol, 1.2 eq) and Cs2CO3(325.82 mg, 1.0 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (172.9 mg, yield=85.5%, purity=91.7%)

4-chloro-7-methoxy-N-methylquinoline-6-carboxamide (125.34 mg, 0.5 mmol, 1.0 eq), N-(3-hydroxy-5-methoxyphenyl)acetamide (108.71 mg, 0.6 mmol, 12 eq) and Cs2CO3(325.82 mg, 1.0 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (120.1 mg, yield=61%, purity=98.9%)

methyl 4-chloroquinoline-6-carboxylate (88.656 mg, 0.4 mmol, 1.0 eq), 3-methoxy-5-(1H-pyrazol-1-yl)phenol (76.08 mg, 0.4 mmol, 1.0 eq) and Cs2CO3(261 mg, 0.8 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (19.8 mg, yield=13.2%, purity=96.43%)

6-bromo-4-chloroquinoline (1.215 g, 5 mmol, 1.0 eq), 3,5-dimethoxyphenol (1 g, 6.5 mmol, 1.3 eq) and Cs2CO3(3.26 g, 10 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 25 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 60 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (2.1 g, yield=99%, purity=85.14%)

methyl 4-chloroquinoline-6-carboxylate (139 mg, 0.6 mmol, 1.2 eq), 3-methoxy-5-(1H-pyrazol-1-yl) phenol (95 mg, 0.5 mmol, 1.0 eq) and Cs2CO3(326 mg, 1.0 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 130° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (171 mg, yield=88.83%, purity=97.36%)

Methyl methyl 4-(3-acetamido-5-methoxyphenoxy) quinoline-6-carboxylate (109.8 mg, 0.3 mmol, 1.0 eq) and LiOH (25.2 mg, 0.6 mmol, 2.0 eq) were added to a round-bottom flask with a magnetic bar. Then 1 ml EtOH and 0.5 ml H2O were added as solvent. The reaction mixture was stirred overnight. When 4-(3-acetamido-5-methoxyphenoxy) quinoline-6-carboxylate was consumed, the pH of reaction mixture was adjusted to 7 and some white solid formed, which was filtered and dried to give the product. (36 mg, yield=34%, purity=77%)

4-chloro-N-methylquinoline-6-carboxamide (44.1 mg, 0.2 mmol, 1.0 eq), N-(3-hydroxy-5-methoxyphenyl) acetamide (36.2 mg, 0.2 mmol, 1.2 eq) and Cs2CO3(130.3 mg, 0.4 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (11 mg, yield=15%, purity=65%)

4-chloro-5-methyl-5H-pyrrolo[3,2-d] pyrimidine (83.8 mg, 0.5 mmol, 1.0 eq), 3,5-dimethoxyphenol (77 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (37.8 mg, yield=13.3%, purity=95%)

4-chloro-6-(trifluoromethyl)quinoline (139 mg, 0.6 mmol, 1.2 eq), N-(3-hydroxy-5-methoxyphenyl)acetamide (90.5 mg, 0.5 mmol, 1.0 eq) and Cs2CO3(325.82 mg, 1.0 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (91 mg, yield=24.2%, purity=99%)

4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine (83.8 mg, 0.5 mmol, 1.0 eq), N-(3-hydroxy-5-methoxyphenyl)acetamide (90.5 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (6.9 mg, yield=2.2%, purity=94.12%)

4-chloro-N-methylquinoline-6-carboxamide (110.25 mg, 0.5 mmol, 1.0 eq), 3-methoxy-5-(1H-pyrazol-1-yl)phenol (95 mg, 0.5 mmol, 1.0 eq) and Cs2CO3(326 mg, 1 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (132.7 mg, yield=70.88%, purity=97.81%)

4-chloro-N, N-dimethylquinoline-6-carboxamide (117.34 mg, 0.5 mmol, 1.0 eq), N-(3-hydroxy-5-methoxyphenyl) acetamide (90.5 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to around-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (124.5 mg, yield=65.6%, purity=83%)

4-chloro-6-iodoquinoline (173.7 mg, 0.6 mmol, 1.2 eq), N-(3-hydroxy-5-methoxyphenyl) acetamide (90.5 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (191.4 mg, yield=88.15%, purity=99%)

4-chloroquinoline-6-carboxamide (103.3 mg, 0.5 mmol, 1.0 eq), 3-methoxy-5-(1H-pyrazol-1-yl) phenol (95 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (117.1 mg, yield=65%, purity=99%)

4-chloro-7-methoxyquinoline-6-carboxamide (119 mg, 0.5 mmol, 1.0 eq), 3-methoxy-5-(pyrimidin-2-yl) phenol (101 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (148 mg, yield=73.36%, purity=98.43%)

4-chloro-7-methoxyquinoline-6-carboxamide (119 mg, 0.5 mmol, 1.0 eq), 3-methoxy-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenol (103 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (182 mg, yield=89.6%, purity=89%)

4-chloroquinoline-6-carboxamide (103.3 mg, 0.5 mmol, 1.0 eq), 3-ethoxy-5-(1H-pyrazol-1-yl) phenol (102.1 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (108.6 mg, yield=58%, purity=91.47%)

4-chloro-7-methoxyquinoline-6-carboxamide (119 mg, 0.5 mmol, 1.0 eq), 3-methoxy-5-(1-methyl-1H-pyrazol-4-yl)phenol (122.4 mg, 0.6 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (189 mg, yield=93.6%, purity=99%)

6-bromo-4-chloroquinoline (144 mg, 0.6 mmol, 1.2 eq), 3-methoxy-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenol (103 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (86.1 mg, yield=41.8%, purity=99%)

6-bromo-4-chloroquinoline (144 mg, 0.6 mmol, 1.2 eq), 3-methoxy-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenol (103 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (18 mg, yield=10.69%, purity=99%)

4-chloro-7-methoxyquinoline-6-carboxamide (119 mg, 0.5 mmol, 1.0 eq), 3,5-dimethoxyphenol (92.4 mg, 0.6 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (124 mg, yield=70%, purity=99%)

4-chloro-6-(trifluoromethyl) quinoline (139 mg, 0.6 mmol, 1.2 eq), 3-hydroxy-5-methoxy-N-methylbenzamide (90.5 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (144 mg, yield=76.5%, purity=99%)

4-chloro-7-methoxyquinoline-6-carboxamide (119 mg, 0.5 mmol, 1.0 eq), 3-hydroxy-5-methoxy-N-methylbenzamide (90.5 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (150 mg, yield=78.5%, purity=99%6)

6-bromo-4-chloroquinoline (145.5 mg, 0.6 mmol, 1.0 eq), 3-hydroxy-5-methoxy-N-methylbenzamide (90.5 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (164 mg, yield=85%, purity=99%)

3-methoxy-5-(1H-pyrazol-1-yl)phenol (70 mg, 0.36 mmol, 1.0 eq), 4-chloro-6,7-dimethoxyquinazoline (91 mg, 0.4 mmol, 1.1 eq) and K2CO3(102 mg, 0.73 mmol, 2 eq) were added to a round-bottom flask with a magnetic bar, then 2 ml DMF was added as a solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 100° C. for 6 h with vigorous stirring. The cooled solution was diluted with water (30 mL) and extracted with ethyl acetate (3×20 mL). Combined organic layers was washed with water (2×20 mL), brine (20 mL) and dried over anhydrous Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (70 mg, yield=50%, purity=99%)

4-chloro-7-methoxyquinoline-6-carboxamide (119 mg, 1.0 mmol, 2.0 eq), (S)-3-methoxy-5-((tetrahydrofuran-3-yl)oxy)phenol (210 mg, 0.6 mmol, 1.2 eq) and K2CO3(276 mg, 2.0 mmol, 4 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (190 mg, yield=92.7%, purity=98.2%)

4-chloro-7-methoxyquinoline-6-carboxamide (119 mg, 0.5 mmol, 1.0 eq), (R)-3-methoxy-5-((tetrahydrofuran-3-yl)oxy)phenol (210 mg, 1.0 mmol, 2 eq) and K2CO3(276 mg, 2.0 mmol, 4.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (140 mg, yield=68.3%, purity=98.9%)

4-chloro-7-methoxyquinoline-6-carboxamide (119 mg, 0.5 mmol, 1.0 eq), 3,5-bis((tetrahydrofuran-3-yl)oxy)phenol (160 mg, 0.6 mmol, 1.2 eq) and K2CO3(276 mg, 2.0 mmol, 4.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (210 mg, yield=92.1%, purity=92.6%)

) 4-chloro-7-methoxyquinoline-6-carboxamide (119 mg, 0.5 mmol, 1.0 eq), 3-methoxy-5-((tetrahydrofuran-3-yl)methoxy)phenol (134 mg, 0.6 mmol, 1.2 eq) and K2CO3(276 mg, 2.0 mmol, 4.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (168 mg, yield=79.2%, purity=98.2%)

4-chloro-7-methoxyquinoline-6-carboxamide (119 mg, 0.5 mmol, 1.0 eq), 3-methoxy-5-(4-methyl-1H-pyrazol-1-yl)phenol (123 mg, 0.6 mmol, 1.2 eq) and K2CO3(276 mg, 2.0 mmol, 4.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (150 mg, yield=74.3%, purity=94.2%)

4-chloro-7-methoxyquinoline-6-carboxamide (142 mg, 0.6 mmol, 1.2 eq), 3-methoxy-5-(3-methyl-1H-pyrazol-1-yl)phenol (204 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (195 mg, yield=96.4%, purity=94.5%)

4-chloro-7-methoxyquinoline-6-carboxamide (118.4 mg, 0.5 mmol, 1.0 eq), 3-(3,5-dimethyl-1H-pyrazol-1-yl)-5-methoxyphenol (131 mg, 0.6 mmol, 1.2 eq) and K2CO3(276 mg, 2.0 mmol, 4.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the produce. (227 mg (containing some solvent), purity=96.23%)

4-chloro-7-methoxyquinoline-6-carboxamide (162.8 mg, 0.69 mmol, 1.0 eq), 3-methoxy-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenol (142.1 mg, 0.69 mmol, 1.0 eq) and K2CO3(381 mg, 2.77 mmol, 4.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (143 mg, yield=50.9%, purity=99.6%)

6-bromo-4-chloro-7-methoxyquinoline (136 mg, 0.5 mmol, 1.0 eq), 3,5-dimethoxyphenol (92.4 mg, 0.6 mmol, 1.2 eq) and K2CO3(276 mg, 2.0 mmol, 4.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (134 mg, yield=68.9%, purity=99%)

6-bromo-4-chloro-7-methoxyquinoline (163.5 mg, 0.6 mmol, 1.2 eq), 3-hydroxy-5-methoxy-N-methylbenzamide (91 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as a white solid. (117 mg, yield=56.1%, purity=99%)

6-bromo-4-chloro-7-methoxyquinoline (195 mg, 0.8 mmol, 1.0 eq), 3-methoxy-5-((tetrahydrofuran-3-yl)oxy)phenol (168 mg, 0.8 mmol, 1.0 eq) and K2CO3(442 mg, 3.2 mmol, 4.0 eq) were added to a round-bottom flask with a magnetic bar, then 5 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 30 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product. (308 mg, yield=92.6%, purity=99%)

6-bromo-4-chloro-7-methoxyquinoline (145.2 mg, 0.6 mmol, 1.2 eq), 3-hydroxy-N-methyl-5-(trifluoromethyl)benzamide (109.5 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product. (195 mg, yield=92%, purity=99.2%)

6-bromo-4-chloroquinoline 1-oxide (154 mg, 0.5 mmol, 1.0 eq), N-(3-hydroxy-5-methoxyphenyl)acetamide (91 mg, 0.5 mmol, 1.0 eq) and K2CO3(276 mg, 2.0 mmol, 4.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product. (144 mg, yield=70.6%, purity=96.7%)

6-bromo-4-chloro-2-methylquinoline (106.6 mg, 0.6 mmol, 1.2 eq), 3-methoxy-5-(1H-pyrazol-1-yl)phenol (95 mg, 0.5 mmol, 1.0 eq) and Cs2CO3(325.8 mg, 1.0 mmol, 2.0 eq) were added to a round-bottom flask with a magnetic bar, then 3 ml DMF was added as solvent. The reaction vessel was evacuated and backfilled with N2three times and protected with a balloon of N2. The reaction mixture was heated at 115° C. for at least 12 h with vigorous stirring. The cooled solution was diluted with 20 ml ethyl acetate and washed with brine. The organic phase was dried over anhydrous Na2SO4and concentrated in vacuum. The residue was purified by silica gel flash chromatography to afford the product as an oil. (142 mg, yield=85.7%, purity=98.98%)

6-bromo-4-(3-methoxy-5-nitrophenoxy)-1-quinolin-1-olate (600 mg, 1.53 mmol, 1 eq) in POCl3(6 mL) was heated at 80° C. for 2 h. Solvent was evaporated under reduced pressure, crude was diluted with sat. Na2CO3solution and extracted with EA (40 mL). Organic layer was washed with water, brine solution, dried over Na2SO4filtered and evaporated under reduced pressure. Crude material was purified by trituration using pentane to afford the product as a pale yellow solid. (500 mg, yield=80%).

Example 92. Cell Culture and Treatment

Six lung cancer cell lines (NCI-H23, NCI-H460, NCI-H596, NCI-H2170, Calu-6 and A549), two colon cancer cell lines (HCT116 and SW460), one breast cancer cell line MDA-MB-231, one gastric cancer cell line NCI-N87, one prostate cancer cell line DU145, one cervical cancer cell line Hela, and one glioblastoma cell line T98G were obtained from ATCC. The T2 HCC cell line was derived from a mouse liver cancer model initiated by a transgene of MYC. All cell lines were cultured in DMEM (Gibco, Cleveland, TN, USA) supplemented with 5% fetal bovine serum (Gibco), penicillin (100 U/mL)—streptomycin (100 μg/mL) (Gibco, Cat. No. 15140-122), 2 mM L-glutamine (Gibco, 200 mM solution, Cat. No. 25030081), and 1 mM sodium pyruvate (Gibco, 100 mM solution, Cat. No. 11360070) at 37° C. in a humidified incubator that was maintained at 5% CO2.

Example 93. Phenotypic Screening Assays

We have previously developed a mechanism-informed phenotypic screening assay to identify novel antimitotic agents. Equipped with a prior understanding of the versatile functions of the chromosomal passenger protein (CPP) complex in orchestrating karyokinesis and cytokinesis, the screening assay is to score for phenotypes typically seen when the CPP complex is disabled. Specifically, the parameters for a positive hit are a temporary elevation of mitotic index (MI) at 24 hours of drug treatment and an accumulation of polyploid cells at 48 hours of drug treatment, indicative of mitotic arrest and cytokinetic failure respectively. These parameters exclude compounds that elicit only a prolonged arrest of cells in mitosis, a phenotype typically provoked by spindle toxins. The screening procedure is briefly summarized here. RPEMYCH2B-GFPcells engineered to express a Histone 2B-EGFP fusion protein were passaged as batches of 96-well plates, 18-24 hours before exposure to the chemical compounds of the present disclosure at concentrations from 1 nM to 30 μM. At 24, 48 or 72 hours after initiation of treatment, cells were analyzed for either an arrest in mitosis or a change in DNA content by GE IN-Cell Analyzer 2000. Testing results of 43 compounds were summarized inFIG.1and Table 2. As set forth in Table 2 below, a value of greater than or equal to 1 nM and less than or equal to 1.0 μM is marked “A”; a value greater than 1.00 μM and less than or equal to 10.0 μM is marked “B”; a value greater than 10.0 μM and less than or equal to 30.0 μM is marked “C”; and a value greater than 30.0 μM is marked “D.”

Example 94. Colony Formation Assay of the Long-Term Effect of Anticancer Agents

Acute cytotoxicity immediately determined after short-term exposure to antimitotic agents often underestimates their potency, because some cancer cells might not die quickly after suffering mitotic defects such as an arrest in mitosis or a cytokinetic failure. Instead, after exposed to antimitotic agents, cells might face multiple possibilities that adversely affect their viability and proliferation in long-term such as permanent arrest of proliferation due to the development of senescence and nonapoptotic cell death by excessive autophagy. Only a small fraction of cells pretreated with an antimitotic agent might resume proliferation and divide to generate viable daughter cells that form colonies. Assay of the ability of cells to form colonies after being exposed to an anticancer agent for a short period of time represents a more accurate approach to document the potency of antimitotic agents. The human lung cancer cell line NCI-H23 in sub-confluence was exposed to compounds #7, #36, and #39 for three days and then transferred to drug-free fresh medium once every 3 days until 12 days after the initiation of treatment. At the end point, cells were photographed after fixed and stained with crystal violet. All three compounds inhibited the long-term proliferative potential of NCI-H23 cells as potent as AZD1152, an inhibitor of the mitotic kinase Aurora B that reached clinical trials (FIG.2).

Example 95. Soft Apr Colony Formation Assay

Measuring the ability of cells to grow in soft agar has been popularly believed as the gold standard assay for cellular transformation in vitro. In the Soft Agar Assay, cells grow from single cells to cell colonies in a semi-solid agar solution that keeps them away from the solid surface and allows growth in an anchorage-independent way.

The anchorage-independent growth of cells is one of the hallmarks of cancer cells. Normal epithelial cells are supported by basement membranes that provide survival and proliferative signals while undergo a type of apoptosis called anoikis when lose their attachment to the extracellular matrix. Cancer cells, in contrast, evade detachment-induced apoptosis, leading to uncontrolled proliferation and metastasis. The Soft Agar Colony Formation Assay allows testing of the therapeutic efficacy of compounds against anchorage-independent 3D growth of cancer cells in vin. The assay was performed in 6-well plates with two layers of agar. For the first, 0.75% agar in DMEM medium was melted in a microwave oven and poured to form a bottom layer. Once solidified, 10-100K cells in 1 ml of DMEM containing 0.35% agar was added to form the top layer, which was later covered with 0.5 ml of DMEM. Cell culture medium was changed once every two days until colonies were ready to photograph. We test the antitumor activity of select compounds in soft agar colony formation assays. Data are summarized inFIG.3. Compounds #7, #8, #15, #36, and #39 effectively suppressed the anchorage-independent growth of a cervical cancer cell line Hela. Similarly, all compounds tested, including #36 and #39, completely blocked the growth of a human lung cancer cell line NCI-H23 in soft agar. Compound #7 also suppressed the growth a colon cancer cell line HCT116 in soft agar. The suppression of growth of these three cancer cell lines in 3D culture is consistent with the potent impact of these compounds on cellular proliferation in 2D culture.

Example 96. The MTT Assay of Cellular Proliferation and Determination of EC50

The MTT assay measures cellular metabolic activity as a proxy for cell viability and involves the conversion of the water-soluble yellow dye MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] into an insoluble purple formazan by the action of mitochondrial reductase. Formazan is then solubilized and its concentration is determined by measuring the optical density (OD) value at a wavelength of 570 nm. The value is in proportional to the number of live cells with excellent linearity up to ˜106cells per well. The MTT assay was used to determine the EC50value, the concentration of a compound that leads to 50% inhibition of cellular proliferation. Briefly, cells were split when growing to the mid-Log phase. Cells in 100 μL of culture medium were seeded into each well of 96-well microplates and cultivated for 15-24 hours to reach a confluence of 20-30% and were then exposed to drugs at concentrations ranging from 1 nM to 30 μM. At the endpoint, 20 μL of a MTT stock solution in DMSO (5 mg/mL) was added to each well that contains 100 μL of DMEM. The microplates were left in the cell culture incubator for 3-4 h before subjected to solubilization and determination of formazan at A570 in a microplate reader (BioTek ELX808iu). The results of these assays are summarized in Table 3. As set forth in table 2 below, a value of greater than or equal to 1 nM and less than or equal to 1.0 μM is marked “A”; a value greater than 1.00 M and less than or equal to 10.0 μM is marked “B”; a value greater than 10.0 μM and less than or equal to 30.0 μM is marked “C”; and a value greater than 30.0 μM is marked “D.” The LG series of compounds displayed potent activity in all human cancer cell lines tested, including six lung cancer cell lines (NCI-H23, NCI-H460, NCI-H596, NCI-H2170, Calu-6 and A549), two colon cancer cell lines (HCT116 and SW460), one breast cancer cell line MDA-MB-231, one gastric cancer cell line NCI-N87, one prostate cancer cell line DU145, one cervical cancer cell line Hela, one glioblastoma cell line T98G, and one liver cancer cell line T2 HCC. Therefore, these compounds might hold a broad utility in the treatment of a large variety of human malignancies.

Xenografts were initiated in immunocompromised (Nu/Nu) mice with the human lung adenocarcinoma cell line NCI-H23 (FIG.4A) and the human breast cancer cell line MDA-MB-231 (FIG.4B). Seven million cells were injected subcutaneously into each mouse and treatment was initiated when the average tumor volumes reached 150 mm3 (n=5/group). Tumor-bearing mice were randomized into different groups to receive either vehicle or indicated compounds. The compounds were administered through oral gavage twice a day for 7 days. For these experiments, all compounds were first dissolved in DMSO and then diluted 1:10 into a mixture containing 50% PEG300 and 49% PBS, 1% Tween 80, pH2.2. 100 ul of drug solution was administered with each dose to each a dose of 25 mg/kg. Tumor volumes were determined from digital caliper raw data by using the formula: Volume (mm3)=(L×W2)/2. The value W (Width) is the smaller of two perpendicular tumor axes and the value L (Length) is the larger of two perpendicular axes. Mean tumor volumes were calculated for each treatment group at the start point (day 0) and the endpoint (day 7). The percentage change of tumor volumes, defined as (Tumor Volumeday8˜Tumor Volumeday0)/Tumor Volumeday0×100% is presented. Compounds #21, #26, #40 and #43 demonstrated the therapeutic efficacy in both mouse tumor models, suppressing the tumor growth and even eliciting tumor regression by compound #43 (FIG.4).